Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bilateral Conjunctivitis (Disorder)
Conditions
Bilateral Conjunctivitis (Disorder)
Trial Timeline
Apr 30, 2021 → Sep 2, 2021
NCT ID
NCT04708821About Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7% is a approved stage product being developed by Ocular Therapeutix for Bilateral Conjunctivitis (Disorder). The current trial status is completed. This product is registered under clinical trial identifier NCT04708821. Target conditions include Bilateral Conjunctivitis (Disorder).
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04708821 | Approved | Completed |
Competing Products
3 competing products in Bilateral Conjunctivitis (Disorder)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 41 |
| ACT-774312 + Placebo | Idorsia | Phase 2 | 47 |
| cataract surgery | GenZum Life Sciences | Phase 3 | 69 |
Other Products from Ocular Therapeutix
Dextenza + Prednisolone AcetateApproved
80
Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal PulsationApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone AcetateApproved
80
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Approved
80
Dextenza 0.4Mg Ophthalmic InsertApproved
80